Over the past month, the Zacks Consensus EPS estimate has shifted 1.13% upward. Novo Nordisk is currently a Zacks Rank #3 (Hold). Valuation is also important, so investors should note that Novo ...

Novo Nordisk › The hits just kept coming for beleaguered Ozempic and Wegovy maker Novo Nordisk (NYSE: NVO) on Thursday. The company, which has been slammed with investor sell-offs since cutting its ...

The average estimate of seven analysts surveyed by Zacks Investment Research was for earnings of 87 cents per share. The maker of engineered products for the aerospace and other industries posted ...

Investing.com - Shares of Biogen (NASDAQ:BIIB) rose in premarket U.S. trading on Thursday after the drugmaker posted ...